Two studies led by Cleveland Clinic researchers found that a variant in a gene involved in androgen synthesis can help predict response to different prostate cancer therapies.
Tempus will provide molecular sequencing and data analysis for patients with metastatic or incurable cancer enrolled in a Cleveland Clinic study.
The test uses the company's SIA platform, a protein biomarker technology that measures different protein isoform populations to assess patient disease states.
Through studies of individuals with an inherited cancer predisposition syndrome, researchers identified germline mutations contributing to sporadic thyroid cancer as well.
The Precision Medicine Exchange Consortium will bring together cancer research institutions to share information and promote genomic profiling in treatment.
The partners will collaborate broadly but start with whole-genome sequencing to find new genes and molecular pathways associated with heart disease.
The partners will use Watson's cognitive capabilities to reduce to minutes from weeks the translation of DNA information to create a genetic profile of a patient.
Besides optimizing open-source code, the company has forged focused partnerships with multiple bioinformatics firms including Edico Genome and Curoverse.
NEW YORK (GenomeWeb) – IBM said today that it has partnered with the Cleveland Clinic to evaluate the use of its Watson supercomputer in a personalized oncology program at the clinic.
NEW YORK (GenomeWeb) – Cleveland Clinic and University Hospitals have received a $1 million donation to support genome sequencing for cancer patients across the Northeast Ohio region.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.